Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Professor Alistair Burns, Emeritus Professor of Old Age Psychiatry at the University of Manchester and previously England’s National Clinical Director for Dementia, observed, "We have reached an exciting time in the field of Alzheimer’s disease treatment. After no new therapies for a generation, we are on the threshold of having a range of new treatments, including a tau-targeted oral therapy, which have the real potential to slow the disease process. This is great news for people with Alzheimer's disease, their families and carers. "
In light of data shared, HMTM has prospective broad applicability for a wide demographic contributing to equity of access to new treatment options. TauRx has initiated regulatory engagement in the UK and the US for intended product approval. Other territories will follow in line with plans to scale commercialisation of HMTM.
actually if not wrong still need fund in , short of money already. waiting approval if fast is 6 if long then don't know.
last time tau say apply 2022 until now no sound
"Conversely, we think M&A or in-licensing agreements may allow for earlier monetisation of Genting's stake, given that large pharmaceutical firms may have M&A interest in TauRx in order to possess the world's only effective Alzheimer's treatment.
"As a plus, M&A could allow TauRx to leverage on such firms' resources to expedite HMTM speed to market," it said in a note today.
Mediforum Pharmaceutical Co., Ltd. (047920) (“Mediforum”) of South Korea and TauRx Pharmaceuticals Ltd. (“TauRx”) of Singapore announce that they signed a termsheet on June 12th 2020 giving Mediforum rights to acquire publishing, manufacturing, and intellectual property rights in Korea to TauRx’s LMTX. LMTX is, globally, the most advanced treatment targeting tau protein in Alzheimer’s disease. By signing this agreement, Mediforum plans to strengthen its position as a leading pharmaceutical company in Korea specializing in dementia.
